Rituximab Inferior to Ocrelizumab for MS Relapse Rituximab Inferior to Ocrelizumab for MS Relapse

The relapse rate among patients with relapsing-remitting multiple sclerosis who were treated with rituximab was higher than among those treated with ocrelizumab, results of a noninferiority study suggest.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news